These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24330023)

  • 21. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M; Cruz LS; Tannus G; Fonseca M
    Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
    Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Delea TE; Rotter J; Taylor M; Chandiwana D; Bains M; El Ouagari K; Kaura S; Morgan GJ
    J Med Econ; 2012; 15(3):454-64. PubMed ID: 22316275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of multiple myeloma bone disease: experimental and clinical data.
    Papamerkouriou YM; Kenanidis E; Gamie Z; Papavasiliou K; Kostakos T; Potoupnis M; Sarris I; Tsiridis E; Kyrkos J
    Expert Opin Biol Ther; 2015 Feb; 15(2):213-30. PubMed ID: 25388648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the biology and treatment of myeloma bone disease.
    Berenson JR
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
    Morgan GJ
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
    Pozzi S; Raje N
    Oncologist; 2011; 16(5):651-62. PubMed ID: 21493759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
    Abe M; Miki H; Nakamura S
    Rinsho Ketsueki; 2015 Aug; 56(8):997-1004. PubMed ID: 26345558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E; Dimopoulos MA; Berenson J
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
    Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
    J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of clodronate in multiple myeloma.
    Jantunen E; Lahtinen R; Laakso M
    Leuk Lymphoma; 1995 Oct; 19(3-4):207-11. PubMed ID: 8535211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
    Ashcroft AJ; Davies FE; Morgan GJ
    Lancet Oncol; 2003 May; 4(5):284-92. PubMed ID: 12732166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumour activity of bisphosphonates in human myeloma cells.
    Shipman CM; Rogers MJ; Apperley JF; Graham R; Russell G; Croucher PI
    Leuk Lymphoma; 1998 Dec; 32(1-2):129-38. PubMed ID: 10037008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
    Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
    Terpos E; Berenson J; Cook RJ; Lipton A; Coleman RE
    Leukemia; 2010 May; 24(5):1043-9. PubMed ID: 20376081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.